National Center for Tumor Diseases/ University of Heidelberg and German Cancer Research Center, Im Neuenheimer Feld 460, 69120 Heidelberg, Germany.
Curr Cancer Drug Targets. 2012 Sep;12(7):797-813. doi: 10.2174/156800912802429319.
Recent research advances have defined a key role of the bone marrow (BM) in multiple myeloma (MM) pathogenesis thereby leading to new treatment paradigms, which aim to target both the tumor cell as well as its BM microenvironment. The incorporation of thalidomide, bortezomib, and lenalidomide into conventional cytotoxic and transplantation regimens in relapsed and refractory, but also in newly diagnosed MM has changed treatment options during the last decade. However, MM remains still incurable. Ongoing translational research aims to identify additional therapeutic targets and to design derived agents, predominantly small molecule inhibitors, with higher potency and less toxicity to further improve MM patient outcome and to overcome drug resistance.
近年来的研究进展明确了骨髓（BM）在多发性骨髓瘤（MM）发病机制中的关键作用，从而产生了新的治疗范例，旨在针对肿瘤细胞及其 BM 微环境。沙利度胺、硼替佐米和来那度胺已被纳入复发和难治性、甚至新诊断的 MM 的常规细胞毒性和移植方案中，这在过去十年改变了治疗选择。然而，MM 仍然无法治愈。正在进行的转化研究旨在确定其他治疗靶点，并设计衍生药物，主要是小分子抑制剂，以提高效力和降低毒性，从而进一步改善 MM 患者的预后并克服耐药性。
